News | October 07, 2022
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Glenmark is the first company in India to market the innovative FDC of Indacaterol
A total of five observations for Goa and 17 for Monroe
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)